Ann: R&D Activities Update and Appendix 3B, page-16

This is the precursor to the real announcement that they are raising capital, IMO this will come in the next few weeks. Happened 6 years ago will happen again. They be mad not to fill the coffers at +10c wouldn't they?? Unfortunately for us when it's all said and done there is really minimal growth in this companies basket of products, which are all specialised and somewhat of a novelty value to clinicians.
by introducing AI into their tests they have essentially devalued their own product. The process is quick and affordable now, great for us as customers, not so great as shareholders. And as our products are niche I don't think we are suddenly going to see hyper growth to offset the drop in price that must have been implemented.
hence the diversification. Management have hit a wall with ferriscan , they must come up with something new to create growth.
its the right approach for sure , looking to grow the company and increase shareholder value, but this approach takes investment and this will be the next phase of RHT.